Skip to content

To evaluate the feasibility of sufentanil combined with propofol and etomidate for gastroscopy

To evaluate the feasibility of sufentanil combined with propofol and etomidate for gastroscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004575
Enrollment
Unknown
Registered
2014-09-21
Start date
2014-04-16
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the anaesthetic regimen of gastroscopy

Interventions

Group P:intravenous administration of propofol when induction
Group E:intravenous administration of etomidate when induction
Group PE:intravenous administration of etomidate and propofol when induction

Sponsors

Department of Anaesthesiology,ShanXi DaYi Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients undergoing gastroscopy with age ranged from 18 to 65, no systemic diseases and allergies will be inclued.

Exclusion criteria

Exclusion criteria: Patients with severe respiratory diseases, hypertension, severe arrhythmia, severe hepatic and renal dysfunction,coagulation disorders,severe obesity and allergic to anaesthetics will be excluded.

Design outcomes

Primary

MeasureTime frame
mean arterial pressure;heart rate;SpO2;induction time;operation time;sedation time;recovery time;drowsiness and weakness;fluid suppliment;addtion of anaesthetic;the rate of discontinued gastroscopy;

Secondary

MeasureTime frame
fluid suppliment;addtion of anaesthetic;the rate of discontinued gastroscopy;

Countries

China

Contacts

Public ContactJianping Chen

ShanXi DaYi Hospital

sxcjp2011@163.com+86 13935126731

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026